secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001104659-23-113410
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q3 2023: GSK royalties $57M, net income $82M, launches XACDURO, positive Phase 3 zoliflodacin
--------------------------------------------------------------------------------

- GSK royalty revenue $57.0M (Q3 2023) vs $65.6M (Q3 2022); net product sales $13.7M.
- Net income $82.0M ($1.26 basic EPS) vs $265.5M ($3.81) in Q3 2022; prior year included gain on sale.
- Launched XACDURO for Acinetobacter HABP/VABP; announced positive Phase 3 zoliflodacin for gonorrhea.
- Appointed Stephen Basso as CFO; repurchased $11.0M of stock in Q3.
- Cash $180.0M; invested $25M in Armata Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/0001104659-23-113410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/tm2329306d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer